{
    "root": "30c7e246-2c1f-bb49-e063-6294a90aad75",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "CARBAMAZEPINE",
    "value": "20250320",
    "ingredients": [
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "CARBAMAZEPINE",
            "code": "33CM23913M"
        }
    ],
    "indications": null,
    "contraindications": "monitoring blood levels increased efficacy safety anticonvulsants ( , laboratory tests ) . adjusted needs individual patient . low initial daily gradual increase advised . soon adequate control achieved , may reduced gradually minimum effective level . medication taken meals .",
    "warningsAndPrecautions": "carbamazepine tablets usp , 200 mg white , capsule-shaped , scored tablets ( debossed \u2018 c \u2019 \u2018 \u2019 either side score ) plain side . bottles 100\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026ndc 69452-312-20 bottles 1000\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 . ndc 69452-312-32 store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) [ usp controlled room temperature ] . protect light moisture . dispense tight , light-resistant , child-resistant container defined usp . medication guide available https : //bionpharma.com/medication-guides . brands listed package insert trademarks respective owners trademarks bionpharma inc. makers brands affiliated endorse bionpharma inc. products . distributed : bionpharma inc. princeton , nj 08540 made india revised:02/2025 fda-05",
    "adverseReactions": "carbamazepine used patients history previous bone marrow depression , hypersensitivity , known sensitivity tricyclic compounds , amitriptyline , desipramine , imipramine , protriptyline , nortriptyline , etc . likewise , theoretical grounds monoamine oxidase ( mao ) inhibitors recommended . carbamazepine , mao inhibitors discontinued minimum 14 days , longer situation permits . coadministration carbamazepine nefazodone may result insufficient plasma concentrations nefazodone active metabolite achieve therapeutic effect . coadministration carbamazepine nefazodone contraindicated .",
    "contraindications_original": "Monitoring of blood levels has increased the efficacy and safety of anticonvulsants (\n \n  see\n                     PRECAUTIONS\n                     ,\n                     Laboratory Tests). Dosage should be adjusted to the needs of the individual patient. A low initial daily dosage with a gradual increase is advised. As soon as adequate control is achieved, the dosage may be reduced very gradually to the minimum effective level. Medication should be taken with meals.",
    "warningsAndPrecautions_original": "Carbamazepine Tablets USP, 200 mg are white, capsule-shaped, scored tablets (debossed \u2018C\u2019 and \u2018M\u2019 on either side of the score) and plain on the other side.\n                  \n                       Bottles of 100\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026NDC 69452-312-20\n \n                  Bottles of 1000\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.NDC 69452-312-32\n                  \n                       Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [see USP Controlled Room Temperature]. Protect from light and moisture.\n \n                  \n                       Dispense in a tight, light-resistant, child-resistant container as defined in the USP.\n \n                  Medication Guide available at https://bionpharma.com/medication-guides.\n                  \n                       The brands listed in this package insert are trademarks of their respective owners and are not trademarks of Bionpharma Inc. The makers of these brands are not affiliated with and do not endorse Bionpharma Inc. or its products.\n \n                  Distributed by: \n  \n                     Bionpharma Inc.\n                       Princeton, NJ 08540\n\n \n                  \n                     MADE IN INDIA\n                  \n                  \n                     Revised:02/2025\n\n \n                  FDA-05",
    "adverseReactions_original": "Carbamazepine should not be used in patients with a history of previous bone marrow depression, hypersensitivity to the drug, or known sensitivity to any of the tricyclic compounds, such as amitriptyline, desipramine, imipramine, protriptyline, nortriptyline, etc. Likewise, on theoretical grounds its use with monoamine oxidase (MAO) inhibitors is not recommended. Before administration of carbamazepine, MAO inhibitors should be discontinued for a minimum of 14 days, or longer if the clinical situation permits.\n                  Coadministration of carbamazepine and nefazodone may result in insufficient plasma concentrations of nefazodone and its active metabolite to achieve a therapeutic effect. Coadministration of carbamazepine with nefazodone is contraindicated."
}